Administrators

You may have missed

Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

BayWa r.e. Eyes Expansion of Standalone Power Systems in Australia

Guidewire Announces $200 Million Accelerated Share Repurchase Program

Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares

Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud

error: Content is protected !!